FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to compounds of formula (I), pharmaceutical compositions, use and method of treatment.
EFFECT: obtaining novel compounds having anti-parasitic activity mediated by Trypanosoma cruzi or Leishmania donovani, and suitable for treating diseases such as Chagas disease, human African trypanosomiasis, African animal trypanosomiasis and leishmaniasis, particularly visceral leishmaniasis.
13 cl, 57 ex
Title | Year | Author | Number |
---|---|---|---|
CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | 2008 |
|
RU2479584C2 |
PYRAZOLE DERIVATIVES AS KALLIKREIN INHIBITORS | 2017 |
|
RU2739447C2 |
EP4 ANTAGONISTS | 2016 |
|
RU2761341C2 |
BICYCLIC DIHYDROPYRIMIDINECARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | 2017 |
|
RU2778478C2 |
NEW COMPOUNDS AND COMPOSITIONS FOR NAMPT INHIBITION | 2011 |
|
RU2617988C2 |
IMIDAZOTRIAZINONE COMPOUNDS | 2011 |
|
RU2603140C2 |
NEW SULPHONAMIDE CARBOXAMIDE COMPOUNDS | 2018 |
|
RU2808572C2 |
NEW COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES | 2018 |
|
RU2785126C2 |
COMPOUNDS FOR THE TREATMENT OF CERTAIN LEUKOSIS | 2019 |
|
RU2804709C2 |
ANTIINFECTIVE COMPOUNDS | 2011 |
|
RU2576662C2 |
Authors
Dates
2020-10-23—Published
2016-08-03—Filed